

Xiao-jun Huang is

Professor of Hematology and Chairman of Peking University Institute of Hematology, Beijing, China; one of the largest HSCT facility worldwide where 1000 allo-HSCT cases were performed each year. Prof. Huang pioneered in experimental research of immunomodulatory agents, clinical study of unmanipulated haplo-HSCT, as well as risk-adapted intervention to reduce GvHD/Relapse, which integrated to "Beijing Protocol" and contributed to the new era "Everyone has a Donor". Professor Huang is currently Chairman of Chinese Association of Hematologists, Executive Director of Asia Pacific Hematology Consortium. Member of International Association for Comparative Research on Leukemia and Related Diseases He has over 350 SCI-indexed publications in NEJM, JCO, Blood, Leukemia, etc.